Efficacy and safety of radiotherapy combined with pyrotinib in treatment of human epidermal growth factor receptor 2-positive breast cancer patients with brain metastasis
10.3760/cma.j.cn115355-20240204-00065
- VernacularTitle:放疗联合吡咯替尼治疗人表皮生长因子受体2阳性乳腺癌脑转移患者的效果及安全性
- Author:
Xianling WANG
1
;
Qian JIANG
Author Information
1. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院放疗科，太原 030013
- Keywords:
Breast neoplasms;
Neoplasm metastasis;
Human epidermal growth factor receptor 2;
Drug therapy, combination;
Pyrotinib
- From:
Cancer Research and Clinic
2024;36(8):622-625
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of radiotherapy combined with pyrotinib for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients with brain metastasis.Methods:A retrospective cohort study was conducted. The clinical data of 36 HER2-positive breast cancer patients with brain metastasis admitted to Shanxi Province Cancer Hospital from January 2021 to January 2023 were retrospectively analyzed. According to the different treatment methods, the patients were divided into the observation group and the control group, 18 cases in each group. The control group was treated with radiotherapy alone, and the observation group was treated with radiotherapy combined with pyrotinib. The objective remission rate, the disease control rate and the incidence of adverse reactions of both groups were compared; Kaplan-Meier method was used for survival analysis.Results:All patients were female and received trastuzumab or trastuzumab combined with pertuzumab chemotherapy or neoadjuvant therapy. The objective response rate of and disease control rate of in the observation group were higher than those in the control group [83.33% (15/18) vs. 50.00% (9/18), 94.44% (17/18) vs. 66.67% (12/18)], and the differences were statistically significant (χ 2 = 4.71, P = 0.034; χ 2 = 4.43, P = 0.034). The incidence of diarrhea in the observation group was higher than that in the control group [55.56% (10/18) vs. 16.67% (3/18), P = 0.035]. However, there were no statistically significant differences in the incidence of nausea, fatigue, and stomatitis between the 2 groups ( P = 1.000). The median progression-free survival (PFS) time in the observation group and the control group was 14.38 months and 12.08 months, respectively, and the difference in PFS was statistically significant ( P = 0.040). The median overall survival (OS) time in the observation group and the control group was 15.78 months and 11.19 months, respectively, and the difference in OS was statistically significant ( P = 0.034). Conclusions:Radiotherapy combined with pyrotinib is effective in the treatment of HER2-positive breast cancer patients with brain metastasis. It has no serious side effects, and can prolong the survival time of patients.
